
Novo Nordisk expects future research and development expenditures will increase at a higher rate than the company’s top line growth. This will ensure that one or more successors are ready once the pharmaceutical firm’s current growth engine, semaglutide, loses its patent.
As well as internal research, one eye will be fixed on potential acquisition candidates for Novo Nordisk. As late as December 2021, the Danish company bought US-based Dicerna for USD 3.3bn – the single biggest acquisition on Novo’s history.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app